August 30, 2016: Santhera Receives FDA Grant in Support of its Ongoing Phase I Trial with Omigapil in Congenital Muscular Dystrophy (Santhera Pharmaceuticals Holding AG)

(Source: Santhera Pharmaceuticals Holding AG) Santhera Pharmaceuticals Holding AG Hammerstrasse 49 CH-4410 Liestal / Switzerland Phone +41 61 906 89 50 Fax +41 61 906 89 51 www.santhera.com Santhera Receives FDA Grant in Support of its Ongoing Phase I Trial with Omigapil in Congenital Muscular Dystrophy Liestal, Switzerland, August 30, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the Office of Orphan Products Development (OOPD) at the US Food and Drug Admin- istration (FDA) has granted Santhera an award of USD 246,000 in support of its ongoing Phase I trial with omigapil (CALLISTO) in patients with congenital muscular dystrophy (CMD). Santhera is conducting CALLISTO in...